A real-world, multi-center, prospective, observational study for PNH in China

Trial Identifier: D7414R00001
Sponsor: AstraZeneca
Start Date: November 2023
Primary Completion Date: November 2025
Study Completion Date: November 2025
Condition: Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Hangzhou, CN
CN, Anhui Hefei, Anhui, CN, 230002
CN, Beijing Beijing, CN, 100044
CN, Beijing Beijing, CN, 100000
CN, Guangdong Guangzhou, Guangdong, CN, 510180
CN, Guangdong Guangzhou, Guangdong, CN, 510080
CN, Guangdong Guangzhou, Guangdong, CN, 510515
CN, Guangxi Nanning, Guangxi, CN, 530021
CN, Guizhou Guiyang, Guizhou, CN, 550004
CN, Hebei Shijiazhuang, Hebei, CN, 050000
CN, Heilongjiang Harbin, Heilongjiang, CN, 150001
CN, Henan Zhengzhou, Henan, CN, 450052
CN, Henan Zhengzhou, Henan, CN, 463599
CN, Henan Zhengzhou, Henan, CN, 450003
CN, Hubei Wuhan, Hubei, CN, 430000
CN, Hubei Wuhan, Hubei, CN, 430030
CN, Hunan Changsha, Hunan, CN, 410005
CN, Hunan Changsha, Hunan, CN, 410008
CN, Jiangsu Nanjing, Jiangsu, CN, 210029
CN, Jiangsu Nantong, Jiangsu, CN, 226001
CN, Jiangsu Xuzhou, Jiangsu, CN, 221002
CN, Jiangxi Nanchang, Jiangxi, CN, 330008
CN, Jiangxi Nanchang, Jiangxi, CN, 330006
CN, Jilin Changchun, Jilin, CN, 130021
CN, Liaoning Shenyang, Liaoning, CN, 110001
CN, Shandong Jinan, Shandong, CN, 250000
CN, Shandong Qingdao, Shandong, CN, 266000
CN, Shandong Zibo, Shandong, CN, 255090
CN, Shangdong Linyi, Shangdong, CN, 276034
CN, Shanghai Shanghai, CN, 200040
CN, Shanghai Shanghai, CN, 200336
CN, Shanxi Taiyuan, Shanxi, CN, 030000
CN, Shanxi Xi 'an, Shanxi, CN, 710068
CN, Shanxi Xi'an, Shanxi, CN, 710061
CN, Sichuan Chengdu, Sichuan, CN, 610072
CN, Sichuan Chengdu, Sichuan, CN, 610041
CN, Tianjin Tianjin, CN, 300052
CN, Tianjin Tianjin, CN, 300020
CN, Tianjin Tianjin, CN, 300190
CN, Yunnan Kunming, Yunnan, CN, 650034